Characterization of the plasma and blood anticoagulant potential of structurally and mechanistically novel oligomers of 4-hydroxycinnamic acids
about
Rational design of potent, small, synthetic allosteric inhibitors of thrombinTargeting the GPIbα binding site of thrombin to simultaneously induce dual anticoagulant and antiplatelet effectsAn update on recent patents on thrombin inhibitors (2010 - 2013)New parenteral anticoagulants in development.Interaction of antithrombin with sulfated, low molecular weight lignins: opportunities for potent, selective modulation of antithrombin function.First steps in the direction of synthetic, allosteric, direct inhibitors of thrombin and factor XaSulfated, low-molecular-weight lignins are potent inhibitorsof plasmin, in addition to thrombin and factor Xa: Novel opportunity for controlling complex pathologies.Sulfated pentagalloylglucoside is a potent, allosteric, and selective inhibitor of factor XIaSulfated low molecular weight lignins, allosteric inhibitors of coagulation proteinases via the heparin binding site, significantly alter the active site of thrombin and factor xa compared to heparin.Identification of the site of binding of sulfated, low molecular weight lignins on thrombinSulfated, low molecular weight lignins inhibit a select group of heparin-binding serine proteases.Potent direct inhibitors of factor Xa based on the tetrahydroisoquinoline scaffold.Designing allosteric regulators of thrombin. Monosulfated benzofuran dimers selectively interact with Arg173 of exosite 2 to induce inhibition.Allosterism-based simultaneous, dual anticoagulant and antiplatelet action: allosteric inhibitor targeting the glycoprotein Ibα-binding and heparin-binding site of thrombin.Recent advances on plasmin inhibitors for the treatment of fibrinolysis-related disorders.
P2860
Q24623182-44F76DA2-EADB-48BF-9014-E9DFCDE58127Q28236023-4B3A0425-45D4-475B-BF2F-2744AA9C163BQ28299898-AD16FA38-7160-482C-8B79-5F742C110205Q33392647-8C5349D9-8641-4B9F-AAFB-E1D1B3930DB2Q33460885-58FC21F9-F6AD-4810-9855-482B0AB0EE12Q33470885-CDDF96F6-51DA-4C64-856E-B00B4E6E8C79Q33519982-7D3E6C95-B1EE-4336-BFC5-E1DCE7C22C88Q34547334-768ED41C-D642-4272-AAA5-58AF57F9CD46Q34620681-4802DF0B-C611-4CC9-B642-464F3A977395Q35242133-D876C8B9-2633-41B2-AE15-1E1E8516534AQ35675434-1D4B0D96-53E1-45E7-84C1-0AC3A54A8CFAQ36129629-9F7D3E81-8DF3-4F00-85B1-49987D667D4CQ36157083-2B5423B7-0524-442F-82C9-77CC7A393431Q36788507-09126039-341A-44F9-9E21-8048CAD5900DQ38198582-FA419E6A-2D04-450A-B705-BF253F983916
P2860
Characterization of the plasma and blood anticoagulant potential of structurally and mechanistically novel oligomers of 4-hydroxycinnamic acids
description
2009 nî lūn-bûn
@nan
2009 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Characterization of the plasma ...... ers of 4-hydroxycinnamic acids
@ast
Characterization of the plasma ...... ers of 4-hydroxycinnamic acids
@en
type
label
Characterization of the plasma ...... ers of 4-hydroxycinnamic acids
@ast
Characterization of the plasma ...... ers of 4-hydroxycinnamic acids
@en
prefLabel
Characterization of the plasma ...... ers of 4-hydroxycinnamic acids
@ast
Characterization of the plasma ...... ers of 4-hydroxycinnamic acids
@en
P2093
P2860
P1476
Characterization of the plasma ...... ers of 4-hydroxycinnamic acids
@en
P2093
Brian L Henry
Donald F Brophy
Erika J Martin
Jay N Thakkar
P2860
P356
10.1097/MBC.0B013E328304E077
P577
2009-01-01T00:00:00Z